Dehydroglyasperin C
Catalog No: CFN96483
Dehydroglyasperin C is a potent NAD(P)H:oxidoquinone reductase (NQO1) and phase 2 enzyme inducer. Dehydroglyasperin C possesses potent antioxidant, cancer chemopreventive, and neuroprotective activities, it has protective effects against chronic diseases caused by reactive oxygen species as well as potential as an antioxidant food additive. Dehydroglyasperin C protects neuronal cells against glutamate-induced oxidative injury through the induction of HO-1 expression, which is, in turn, activated maybe through Nrf2-Keap1 and PI3K/AKT signaling pathways.
Dehydroglyasperin D
Catalog No: CFN96516
Dehydroglyasperin D exhibits anticancer, anti-inflammatory, anti-obesity, antioxidant and anti-aldose reductase effects, it inhibits the proliferation of HT-29 human colorectal cancer cells through direct interaction with phosphatidylinositol 3-kinase; it also mediates suppression of both COX-2 expression and the MLK3 signalling pathway through direct binding and inhibition of MLK3. Dehydroglyasperin D shows strong ferric reducing activities and effectively scavenged DPPH, ABTS(+), and singlet oxygen radicals.
Dehydroleucodine
Catalog No: CFN96587
Dehydroleucodine has antidiarrheal, anti-inflammatory, anti-microbial, embryotoxicity, gastric cytoprotective, anti-cancer activities. Dehydroleucodine has an important inhibitory effect in cellular pathways regulating adipocyte differentiation by modulating the PPARγ expression, which is known to play a pivotal role during adipogenesis. Dehydroleucodine may be attributed to interference with multiple targets on the level of transcription factors, such as NF-kappaB, and cytokines. Dehydroleucodine induces a TP73-dependent transcriptional regulation of multiple cell death target genes in human glioblastoma cells.
